Cambridge, UK: 

o2h Ventures is honoured to have been Highly Commended in the Impact Award category at the Enterprise Investment Scheme Association (EISA) Awards 2025, held at the House of Lords on 19 June. The commendation highlights o2h Ventures’ pivotal investment into Exonate, a Cambridge-based biotech company developing an innovative, non-invasive eye drop treatment for diabetic eye disease and wet age-related macular degeneration (AMD).

The EISA Impact Award celebrates EIS/SEIS investments that deliver measurable benefits to society or the environment. Exonate’s breakthrough therapy has the potential to transform retinal disease treatment, offering millions of patients worldwide a safer, needle-free alternative to current invasive injections.

This recognition underscores o2h Ventures’ broader commitment to nurturing and supporting early-stage biotech companies in the UK that are addressing diseases of high unmet medical need. In addition to Exonate, the o2h Ventures portfolio includes more than 36 companies working in areas such as anti-aging, cancer, depression, disease of the ear and eye, psoriasis, Idiopathic Pulmonary Fibrosis and infectious diseases. 

Many of these ventures are university spinouts from Cambridge, Oxford, UCL, Dundee, Sussex, and Nottingham, reflecting o2h Ventures’ dedication to translating cutting-edge research into real-world therapies. o2h Ventures often takes an active role in these biotechs—leading funding rounds, supporting strategic development, and holding board positions to help them scale and succeed.

For more information about the EISA Awards and to view the full list of finalists, please visit: https://eisa.org.uk/events/eisa-awards-2025